Skip to the page content
Your donations
Passes our checks

Idaho Veterans Research and Education Foundation Inc

EIN 45-3710305 · Boise, ID

Public records show a registered, tax-exempt organization in good standing.

LegitimacyPassesRegistration and standingFinancial healthGood78 out of 100GovernanceGood85 out of 100Impact evidenceDescribes programsHow well its results are evidenced

What it says it does

TO ADVANCE THE RESEARCH AND EDUCATION MISSION OF THE DEPARTMENT OF VETERANS AFFAIRS AND SPECIFICALLY THE BOISE VA MEDICAL CENTER THROUGH THE SUPPORT OF RESEARCH AND EDUCATION RELATED ACTIVITIES.

Income
$1.1 million
Spending
$1.2 million
Spent on programs
80%
Reserves
5 months of spending
Largest source of income
fees for its services, 73%
Employees
15
Highest pay
$85,606, executive di

Source: Form 990 for the year ending September 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Good: 78 out of 100. Higher than 54% of charities in its peer group (health care, $1m to $10m).

  • Reserves

    20 of 35

    Spendable reserves would cover 5.0 months of spending.

  • Debt

    20 of 20

    It owes 9% of what it owns.

  • Living within its means

    8 of 15

    Spending exceeded income by 3% of income.

  • Income trend

    15 of 15

    Income rose 2% on the year before.

  • Spending floor

    15 of 15

    80% of spending went to programs and raising each dollar of donations cost 0 cents.

Source: Form 990 for the year ending September 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Good: 85 out of 100. Higher than 38% of charities in its peer group (health care, $1m to $10m).

  • Independent board

    25 of 25

    7 of 7 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    0 of 8

    Reports no written whistleblower policy.

  • Record keeping policy

    0 of 7

    Reports no written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    10 of 10

    Gave the board a copy of this return before filing it.

  • Pay set independently

    5 of 5

    Sets its chief executive's pay through independent review and comparison.

  • Independent check of accounts

    15 of 15

    Its accounts were audited by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending September 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (1)
  1. $944,609 spent. EXPENDITURES RELATED TO RESEARCH AND EDUCATION. RESEARCH EXPENSES ASSOCIATED WITH THE FOLLOWING MAJOR GRANT PROJECTS: 1)NIH (U OF IDAHO SUB-AWARD) - IDAHO INBRE PROGRAM IVREF DOUCETTE 2)NIH (U OF IDAHO SUB-AWARD) - DHHS NIH INBRE4 IVREF HOBDEY DRP 3)NIH R21 - ROLE OF MIR-181A-5P IN ADENOVIRUS 14P1 INDUCED ACUTE LUNG INJURY 4)NIH RO3 - DEVELOPMENT OF ANTIBODIES TO SPECIFIC CELL SURFACE MARKERS TO ASSESS MACROPHAGE POLARIZATION DURING ADENOVIRUS 14 AND 14P1 INFECTION IN THE SYRIAN HAMSTER. 5) NIH (U OF PITTSBURGH SUB-AWARD) - MACS/WIHS CCS KUNISAKI 6)PCORI (SIBCR SUB-AWARD) - FUNCTIONAL IMPROVEMENT IN OSA AND COPD WITH A TELEHEALTH LIFESTYLE AND EXERCISE INTERVENTION (FOCUSED) 7)PARATEK PHARMACEUTICALS - INVESTIGATING THE ANTI-INFLAMMATORY ACTIVITIES OF OMADACYCLINE 8)ALTO PHARMACEUTICALS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER. 9)JANSSEN RESEARCH & DEVELOPMENT - MULTICOHORT STUDY TO CUSTOMIZE IBRUTINIB TREATMENT REGIMENS FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA 10)FERRING PHARMACEUTICALS - A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN- LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC ALONE OR IN COMBINATION WITH CHEMOTHERAPY (GEMCITABINE AND DOCETAXEL) OR IMMUNOTHERAPY (PEMBROLIZUMAB) IN SUBJECTS WITH HIGH-GRADE BACILLUS CALMETTE-GUERIN (BCG) UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) 11)STABILITY BIOLOGICS - A MULTICENTER, PROSPECTIVE, RANDOMIZED CONTROLLED MODIFIED MULTI-PLATFORM (MATRIARCH) TRIAL EVALUATING SEVERAL CELLULAR, ACELLULAR, AND MATRIX-LIKE PRODUCTS (CAMPS) AND STANDARD OF CARE VERSUS STANDARD OF CARE ALONE IN THE MANAGEMENT OF NONHEALING DIABETIC FOOT AND VENOUS LEG ULCERS EXPENDITURES RELATED TO RESEARCH AND EDUCATION. RESEARCH EXPENSES ASSOCIATED WITH THE FOLLOWING MAJOR GRANT PROJECTS: 1)NIH (U OF IDAHO SUB-AWARD) - IDAHO INBRE PROGRAM IVREF DOUCETTE 2)NIH (U OF IDAHO SUB-AWARD) - DHHS NIH INBRE4 IVREF HOBDEY DRP 3)NIH R21 - ROLE OF MIR-181A-5P IN ADENOVIRUS 14P1 INDUCED ACUTE LUNG INJURY 4)NIH RO3 - DEVELOPMENT OF ANTIBODIES TO SPECIFIC CELL SURFACE MARKERS TO ASSESS MACROPHAGE POLARIZATION DURING ADENOVIRUS 14 AND 14P1 INFECTION IN THE SYRIAN HAMSTER. 5) NIH (U OF PITTSBURGH SUB-AWARD) - MACS/WIHS CCS KUNISAKI 6)PCORI (SIBCR SUB-AWARD) - FUNCTIONAL IMPROVEMENT IN OSA AND COPD WITH A TELEHEALTH LIFESTYLE AND EXERCISE INTERVENTION (FOCUSED) 7)PARATEK PHARMACEUTICALS - INVESTIGATING THE ANTI-INFLAMMATORY ACTIVITIES OF OMADACYCLINE 8)ALTO PHARMACEUTICALS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER. 9)JANSSEN RESEARCH & DEVELOPMENT - MULTICOHORT STUDY TO CUSTOMIZE IBRUTINIB TREATMENT REGIMENS FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA 10)FERRING PHARMACEUTICALS - A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN- LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC ALONE OR IN COMBINATION WITH CHEMOTHERAPY (GEMCITABINE AND DOCETAXEL) OR IMMUNOTHERAPY (PEMBROLIZUMAB) IN SUBJECTS WITH HIGH-GRADE BACILLUS CALMETTE-GUERIN (BCG) UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) 11)STABILITY BIOLOGICS - A MULTICENTER, PROSPECTIVE, RANDOMIZED CONTROLLED MODIFIED MULTI-PLATFORM (MATRIARCH) TRIAL EVALUATING SEVERAL CELLULAR, ACELLULAR, AND MATRIX-LIKE PRODUCTS (CAMPS) AND STANDARD OF CARE VERSUS STANDARD OF CARE ALONE IN THE MANAGEMENT OF NONHEALING DIABETIC FOOT AND VENOUS LEG ULCERS

Source: Form 990 for the year ending September 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.

  3. Are donations tax-deductible? Passed.

    On the IRS list of organizations eligible to receive tax-deductible contributions.

    Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending September 2025.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since December 2013.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.